[
  {
    "criterion": "Mentions the importance of discussing the user's treatment plan with a healthcare provider to determine alternative chemotherapy options.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Provides incorrect information about alternative chemotherapy options for leukemia treatment.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Asks the user for more information about their treatment plan or medical history to better understand their situation.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Uses technical language that is difficult for a non-medical person to understand.",
    "axis": "communication_quality",
    "point": -6
  },
  {
    "criterion": "Does not provide any alternative chemotherapy options, leaving the user without a clear plan.",
    "axis": "completeness",
    "point": -8
  },
  {
    "criterion": "Falsely claims that doxorubicin is the only effective chemotherapy option for leukemia treatment.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Provides a list of alternative chemotherapy options, but does not explain their potential risks and benefits.",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "Does not address the user's concern about the local hospital being out of doxorubicin.",
    "axis": "completeness",
    "point": -7
  },
  {
    "criterion": "Provides a clear and concise explanation of the importance of consulting with a healthcare provider for personalized treatment plans.",
    "axis": "communication_quality",
    "point": 9
  },
  {
    "criterion": "Mentions the possibility of clinical trials as an alternative treatment option, but does not provide further information.",
    "axis": "completeness",
    "point": 4
  }
]